New drug combo shows promise for rare ovarian cancer

NCT ID NCT03531645

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot phase II study tests whether the drugs fulvestrant and abemaciclib can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the drugs before and after surgery. The goal is to see how many patients achieve a partial response, complete response, or stable disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fulvestrant (Faslodex) and abemaciclib
What this could lead to: If it works, this could offer a new treatment option to control low-grade serous ovarian cancer before and after surgery.
What could go wrong: This is a very small pilot study with only 18 participants, so results may not apply to all patients. The drugs are already approved for other cancers but are experimental for this type of ovarian cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW GRADE SEROUS OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female reproductive organ cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.